- The U.S. regulator approves Flamel Technologies' (FLML) Vazculep (phenylephrine hydrochloride) for the treatment of clinically important hypotension in the operating room anesthesia setting.
- Vazculep is the second product approval for the company in the Unapproved Marketed Drugs space. Bloxiverz was approved in May 2013.
FDA clears Vazculep
Recommended For You
More Trending News
About AVDL Stock
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| AVDL | - | - |
| Avadel Pharmaceuticals plc | ||